Precision NanoSystems (Cytiva)

Vancouver, BC, Canada
Find alternatives to Precision NanoSystems (Cytiva) for mRNA →
Reagent / Material Supplier
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
60.5
Signal Score
○ FDA Inspections ○ Clinical Trials ✓ SEC Filings (24) ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Precision NanoSystems (Cytiva)

Signal Score
60.5/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
Vancouver, BC, Canada
Modalities
mRNA
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Precision NanoSystems (Cytiva)

Reagent/raw material supplier.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesmRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 68.0
Parent company: Cytiva
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
24 SEC filings with industry mentions on record (shown, not scored)
SEC Filings24 with industry mentions (not scored)
Parent company: Cytiva
Financial assessment: 68.0/100
Capacity 53.0
1 manufacturing site: Vancouver, BC
Modalities: mRNA
Capacity assessment: 53.0/100
Sites: Vancouver, BC
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Vancouver, BC
Modalities: mRNA
Capacity assessment: 53.0/100

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (100 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the group's board only shows its ~100 newest postings across all units, so we can't separate this business's roles. We'd rather show no number than one that isn't really this company's.
Source: danaher.wd1.myworkdayjobs.com · Checked Nov 20, 2026

Financial Intelligence

10-Q 2026-10-21 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, the manufacture of instruments that are used in OTL arrangements, replacing equipment, purchasing buildings, supporting new product development and improving information technology systems."
8-K 2026-10-21 0 keyword mentions
"Item 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION: On October 21, 2026, Danaher Corporation (“Danaher”) issued a press release announcing financial results for the quarter ended September 25, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. This Current Report on Form 8-K and the press release attached hereto are being furnished by Danaher pursuant to Item 2.02 of Form 8-K."
8-K 2026-10-13 0 keyword mentions
"Item 5.02: DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS"
"Item 8.01 OTHER EVENTS: As previously disclosed in that certain Current Report on Form 8-K filed by the Company on August 3, 2026, on August 4, 2026, Steven M. Rales, Chairman of the Board and co-founder of the Company, and Mitchell P. Rales, Chairman of the Executive Committee and co-founder of the Company, were each granted restricted stock units with respect to 500,000 shares of the Company’s common stock (the “Founder RSUs”) as well as awards of stock options."
8-K 2026-08-03 0 keyword mentions
"Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS: Appointment of Julie Sawyer Montgomery as President and Chief Executive Officer"
"Item 5.02 Transition of Rainer M. Blair: In connection with Ms. Sawyer Montgomery’s succession, on August 3, 2026, the Company also announced that, effective as of the Effective Date, Rainer M. Blair will cease serving as President and CEO of the Company, and will resign as a member of the Board and from each of the Executive, Finance and Science & Technology Committees of the Board. As further discussed below, to support the transition, Mr. Blair has agreed to continue employment as Senior Advi"
"Item 5.02 Special Equity Awards: On July 31, 2026, the Compensation Committee of the Board (the “Compensation Committee”) approved a Long-Term Growth Award to Matthew Gugino, the Company’s Chief Financial Officer, with a target award value of $12,500,000 and on the same terms as described above for the Long-Term Growth Award granted to Ms. Sawyer Montgomery."
10-Q 2026-07-21 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, the manufacture of instruments that are used in OTL arrangements, replacing equipment, purchasing buildings, supporting new product development and improving information technology systems."
8-K 2026-07-21 0 keyword mentions
"Item 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION: On July 21, 2026, Danaher Corporation (“Danaher”) issued a press release announcing financial results for the quarter ended June 26, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. This Current Report on Form 8-K and the press release attached hereto are being furnished by Danaher pursuant to Item 2.02 of Form 8-K."
8-K 2026-06-03 0 keyword mentions
"Item 8.01 OTHER EVENTS: On June 3, 2026, Danaher Corporation, a Delaware corporation (the “Company”), and its wholly owned subsidiary DH Masi Finance Inc., a Delaware corporation (the “Issuer”), entered into a note purchase and guaranty agreement among the Company, the Issuer and the institutional accredited investors named therein (the “Note Purchase Agreement”), relating to the issuance and sale of (i) CHF 119,500,000 aggregate principal amount of the Issuer’s 1.65% Senior Notes, Series A due "
8-K 2026-04-29 0 keyword mentions
10-Q 2026-04-21 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, the manufacture of instruments that are used in OTL arrangements, replacing equipment, purchasing buildings, supporting new product development and improving information technology systems."
8-K 2026-04-21 0 keyword mentions
8-K 2026-04-17 0 keyword mentions
10-K 2026-02-24 13 keyword mentions
"government could also control our allocation of manufacturing capacity."
"These therapeutics include protein-based and other biological therapies as well as a new emerging class of highly-targeted therapies such as cell and gene therapies and nucleic acid-based therapies."
"Typical users of these products and services include pharmaceutical and biopharmaceutical companies, translational medicine institutions, biotechnology companies and contract manufacturing organizations."
8-K 2026-02-17 0 keyword mentions
8-K 2026-02-10 0 keyword mentions
8-K 2026-01-28 0 keyword mentions
8-K 2026-01-12 0 keyword mentions
8-K 2025-11-06 0 keyword mentions
10-Q 2025-10-21 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, increasing manufacturing capacity, replacing equipment, purchasing facilities, supporting new product development and improving IT systems."
10-Q 2025-07-22 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"29 Table of Contents LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, replacing equipment, purchasing facilities, supporting new product development and improving IT systems."
10-Q 2025-04-22 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, replacing equipment, purchasing facilities, supporting new product development and improving IT systems."
10-K 2025-02-20 12 keyword mentions
"government could also control our allocation of manufacturing capacity."
"These therapeutics include protein-based and other biological therapies as well as a new emerging class of highly-targeted therapies such as cell and gene therapies and nucleic acid-based therapies."
"Typical users of these products and services include pharmaceutical and biopharmaceutical companies, translational medicine institutions, biotechnology companies and contract manufacturing organizations."
10-Q 2024-10-22 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, replacing equipment, the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, supporting new product development and improving IT systems."
10-Q 2024-07-23 5 keyword mentions
"government could also control our allocation of manufacturing capacity."
"Additionally, while the Company believes that emerging biotech customers are continuing to manage their liquidity, we also believe they are prioritizing select cell and gene therapy projects, and we further believe that the improvement in the overall funding environment in the period is a positive leading indicator for these customers."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
10-Q 2024-04-23 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, replacing equipment, the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, supporting new product development and improving IT systems."
Source: SEC EDGAR · Retrieved Nov 21, 2026

Frequently Asked Questions About Precision NanoSystems (Cytiva)

What is Precision NanoSystems (Cytiva)'s CDMO Signal Score?
Precision NanoSystems (Cytiva) has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Precision NanoSystems (Cytiva) for a manufacturing program?
Use the free AI matchmaker to compare Precision NanoSystems (Cytiva) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs →

Similar CDMOs

Evonik Health Care
Birmingham, AL · Vancouver, BC
Signal Score: 81.5
mRNA, Biologics
CCRM
Toronto, ON, Canada
Signal Score: 59.0
Cell Therapy, mRNA
Acuitas Therapeutics
Vancouver, BC
Signal Score: 56.5
mRNA
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 90.1
Biologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein

Compare Precision NanoSystems (Cytiva) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Precision NanoSystems (Cytiva)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.